Clinical evaluation and promotion of Qingchang suppository in the treatment of mild and moderate active ulcerative proctitis

Qingchang suppository for the treatment of mild and moderate active ulcerative proctitis: a prospective, randomized controlled multicenter clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017826

Enrollment

Unknown

Registered

2018-08-16

Start date

2018-09-01

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative proctitis

Interventions

Group 1:Qingchang suppository

Group 2:SASP suppository

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) mild to moderate active ulcerative proctitis; 2) TCM syndrome of dampness and heat in colon; 3) age between 18 and 70 years; 4) signing informed consent.

Exclusion criteria

Exclusion criteria: 1) severe active ulerative colitis; 2) ulcerative colitis affecting the colonic segments except for rectum; 3) suspecting colonic or rectal cancer; 4) recieving medications treating ulcerative colitis (SASP, immunosuppressant, glucocorticoid,etc) within 1 month.

Design outcomes

Primary

Measure	Time frame
Mayo scores of ulcerative colitis;TCM symptom scores;colonscopy examination;pathological results of rectal mucosa;	—

Secondary

Measure	Time frame
ESR;CRP;	—

Countries

China

Contacts

Public ContactLin Jiang

Longhua Hosptial Affiliated to Shanghai University of TCM

linjiang@longhua.net+86 18917763419

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026